Li Yaqiang, Liu Jie, Zhu Yuanyuan, Xue Min, He Jiale
Department of Neurology, People's Hospital of Lixin Country, Bozhou, China.
Department of Neurology, First Affiliated Hospital of Anhui University of Science and Technology (First People's Hospital of Huainan), Huainan, China.
Front Neurol. 2024 Dec 19;15:1415977. doi: 10.3389/fneur.2024.1415977. eCollection 2024.
For investigating an influence on butylphthalide sodium chloride injection combined with edaravone dextromethorphan on neurological function, serum free radical levels, and serum inflammatory factor levels in sufferers having acute progressive cerebral infarction (APCI).
A cohort of 200 patients, afflicted by APCI and admitted to our healthcare institution between December 2018 through July 2023, were incorporated into this longitudinal prospective analysis. Employing a random number table methodology, the patient cohort was bifurcated into a control group ( = 100) and an observation group ( = 100). The control group is treated with butylphthalide sodium chloride injection and the study group is treated with edaravone dexborneol, based on the control group. The posttreatment curative efficacy on the two groups is recorded, and treatment of both the two groups is compared. Before and after neurological function indexes (NIHSS and BI), inflammatory factor indexes (hs-CRP, IL-8, and TNF-a), serum free radical levels (ROS, NO, and SOD), and contrasted between the two groups of treatment effect during therapy.
Compared with the control (65%), the observation group exhibited a significantly higher effective rate of around 89%. In the observation group, the improvement in NIHSS, and Barthel index scores; inflammatory indexes including hs-CRP, IL-8, and TNF-a; and serum free radical levels including ROS, NO, and SOD in peripheral blood was better than the control group, with significant difference (all P<0.05).
The clinical efficacy of edaravone dexborneol combined with butylphthalide sodium chloride injection in the treatment of acute progressive cerebral infarction is precise, which can effectively reduce the level of inflammatory factors and serum free radicals in patients, improve the neurological function of patients, and reduce the damage of cerebral cells, and the safety is high.
探讨丁苯酞氯化钠注射液联合右莰醇对急性进展性脑梗死(APCI)患者神经功能、血清自由基水平及血清炎症因子水平的影响。
选取2018年12月至2023年7月在我院收治的200例APCI患者纳入本纵向前瞻性分析。采用随机数字表法将患者分为对照组(n = 100)和观察组(n = 100)。对照组给予丁苯酞氯化钠注射液治疗,观察组在对照组基础上给予右莰醇治疗。记录两组治疗后的疗效,并比较两组治疗情况。对比两组治疗前后神经功能指标(NIHSS和BI)、炎症因子指标(hs-CRP、IL-8和TNF-a)、血清自由基水平(ROS、NO和SOD)及治疗效果。
与对照组(65%)相比,观察组有效率显著更高,约为89%。观察组外周血NIHSS和Barthel指数评分改善;hs-CRP、IL-8和TNF-a等炎症指标;以及ROS、NO和SOD等血清自由基水平均优于对照组,差异有统计学意义(均P<0.05)。
右莰醇联合丁苯酞氯化钠注射液治疗急性进展性脑梗死的临床疗效确切,可有效降低患者炎症因子及血清自由基水平,改善患者神经功能,减轻脑细胞损伤,且安全性高。